Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily

American Journal of Gastroenterology

Volumn 104, Issue 8, 2009, Pages 2005-2013

  Gasiorowska, Anita ^a   Navarro Rodriguez, Tomas ^a   Wendel, Christopher ^a   Krupinski, Elizabeth ^a   Perry, Zvi H ^a   Koenig, Kristina ^a   Moty, Bridget ^a   Powers, Jeannette ^a   Fass, Ronnie ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; ESOPHAGUS INJURY; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HUMAN; MALE; PATIENT MONITORING; PH MEASUREMENT; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; DRUG ADMINISTRATION SCHEDULE; DUODENOGASTRIC REFLUX; ESOPHAGEAL PH MONITORING; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; REMISSION INDUCTION; TREATMENT FAILURE;

EID: 68349157689     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.240     Document Type: Article

References (44)

1. Locke GR III, Talley NJ, Fett SL et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmstead County, Minnesota. Gastroenterology 1997;112:1448-56.
2. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976;21:953-6.
3. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005;100:283-9.
4. Dent J, El-Serag HB, Wallander MA et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710-7.
5. Sifrim D, Castell DO, Dent J et al. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004;53:1024-31.
6. Ronkainen J, Aro P, Storskrubb T et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005;40:275-85.
7. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease-current concepts and dilemmas. Am J Gastroenterol 2001;96:303-14.
8. Dekel R, Morse C, Fass R. The role of proton pump inhibitors in gastrooesophageal reflux disease. Drugs 2004;4:277-95.
9. Coron E, Hatlebakk JG, Galmiche JP. Medical therapy of gastroesophageal reflux disease. Curr Opin Gastroenterol 2007;23:434-9.
10. Chiba N, De Gara CJ, Wilkinson JM et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-810.
11. Fass R, Mackel C, Sampliner RE. 24-hour pH monitoring in symptomatic patients without erosive esophagitis who did not respond to antireflux treatment. J Clin Gastroenterol 1994;19:97-9.
12. Fass R, Shapiro M, Dekel R et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 2005;22:79-94.
13. Klinkenberg-Knol EC, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
14. Fass R, Murthy U, Hayden CW et al. Omeprazole 4. mg once a day is equally effective as lansoprazole 3. mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000;14:1595-603.
15. Zerbib F, Duriez A, Roman S et al. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008;57:156-60.
16. Schey R, Shapiro M, Navarro-Rodriguez T et al. Comparison of the different characteristics of sensed reflux events among different heartburn groups. J Clin Gastroenterol; published online 1. September 2008 [e-pub ahead of print].
17. Bredenoord AJ, Weusten BL, Curvers WL et al. Determinants of perception of heartburn and regurgitation. Gut 2006;55:313-8.
18. Weusten BL, Akkermans LM, vanBerge-Henegouwen GP et al. Symptom perception in gastroesophageal reflux disease is dependent on spatiotemporal reflux characteristics. Gastroenterology 1995;108:1739-44.
19. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006;367:2086-100.
20. Tack J, Koek G, Demedts I et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004;99:981-9.
21. Koek GH, Sifrim D, Lerut T et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003;52:1397-402.
22. Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80.
23. Wiener GJ, Morgan T, Copper JB et al. Ambulatory 24-hour esophageal pH monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci 1988;33:1127-33.
24. Wiener GJ, Richter JE, Cooper JB et al. The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 1988;83:358-61.
25. Bechi P, Pucciani F, Baldini F et al. Long-term ambulatory enterogastric reflux monitoring. Validation of a new fiberoptic technique. Dig Dis Sci 1993;38:1297-306.
26. Dickman R, Fass R. Ambulatory esophageal pH monitoring: new directions. Dig Dis 2006;24:172-80.
27. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996;111:1192-9.
28. Marshall RE, Anggainsah A, Owen WA et al. The relationship between acid and bile reflux and symptoms in gastro-oesophageal reflux disease. Gut 1997;40:182-7.
29. Barrett MW, Myers JC, Watson DI et al. Dietary interference with the use of Bilitec to assess bile reflux. Dis Esophagus 1999;12:60-4.
30. Zacharioudakis G, Chrysos E, Athanasakis E et al. Is there any mediterranean diet not affecting bilitec assessment of bile reflux? Digestion 2004;70:84-92.
31. Locke GR, Talley NJ, Weaver AL et al. A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994;69:539-47.
32. Brazier JE, Harper R, Jones NM et al. Validating the SF-3. health survey questionnaire: new outcome measure for primary care. Br Med J 1992;305:160-4.
33. Jenkinson C, Coulter A, Wright L. Short form 36 (SF 36. health survey questionnaire: normative data for adults of working age. Br Med J 1993;306:1437-40.
34. Zerbib F, Roman S, Ropert A et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;101:1956-63.
35. Tutuian R, Vela MF, Hill EG et al. Characteristics of symptomatic reflux episodes on acid suppressive therapy. Am J Gastroenterol 2008;103:1090-6.
36. Vela MF, Camacho-Lobato L, Srinivasan R et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001;120:1599-606.
37. Fass R, Sontag SJ, Traxler B et al. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006;4:40-56.
38. Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 2007;67:1521-30.
39. Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin Gastroenterol Hepatol 2008;6:393-400.
40. Koek GH, Tack J, Sifrim D et al. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol 2001;96:2033-40.
41. Castell DO, Richter JE, Robinson M et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996;91:1749-57.
42. Sharma VK, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001;15:227-31.
43. Richter JE, Kahrilas PJ, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-65.
44. Hetzel DJ, Dent J, Reed WD et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988;95:903-12.